NuCana Announces ADS Ratio Change
Change in ADS Ratio: NuCana plc will change the ratio of its American Depository Shares (ADSs) from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective August 11, 2025, which is akin to a one-for-two hundred reverse split but will not affect shareholders' proportional equity interests.
Company Overview: NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, with ongoing studies for its product candidates NUC-7738 and NUC-3373 aimed at enhancing efficacy and safety compared to traditional chemotherapy agents.
Trade with 70% Backtested Accuracy
Analyst Views on NCNA
About NCNA
About the author
Major Stocks Including IBEX, Tesla, IonQ, and Warner Bros. Discovery Rise on Friday
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones index dropping over 100 points on Friday, while several companies, including IBEX Limited, saw significant gains after reporting strong financial results.
IBEX Limited's Financial Success: IBEX Limited's shares surged 33.7% to $40.74 after reporting quarterly earnings of 87 cents per share, exceeding analyst expectations, and providing optimistic sales guidance for FY26.
NuCana Gets Compliance Notice from Nasdaq
Compliance Notification: NuCana has received formal notification from Nasdaq confirming compliance with all continued listing criteria, including the $1.00 minimum bid price requirement.
Stock Performance: Following the announcement, NuCana's stock (NCNA) rose by 2.44% in premarket trading, reaching a price of $2.93.
